The city of Savannah, Georgia, currently has 6 active clinical trials seeking participants for Alzheimer's Disease research studies.
A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)
NCT05026866
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).
Gender:
All
Ages:
Between 65 years and 80 years
Trial Updated:
06/17/2024
Locations: Meridian Clinical Research, LLC, Savannah, Georgia
Conditions: Alzheimer Disease
Register for Updates
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
NCT05531526
Recruiting
This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to evaluate the efficacy and safety of AR1001 for the treatment of participants with early AD.
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
06/06/2024
Locations: iResearch, Savannah, Georgia
Conditions: Alzheimer Disease
Register for Updates
A Study to Evaluate Efficacy and Safety of Intravenous ACU193 in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
NCT06335173
Recruiting
The primary purpose of this study is to evaluate the efficacy of ACU193 infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
05/29/2024
Locations: CenExel - iResearch Savannah, Savannah, Georgia
Conditions: Alzheimer Disease
Register for Updates
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
NCT05738486
Recruiting
This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptomatic Alzheimer's disease (AD) and explore participant characteristics that might predict risk of ARIA.
Gender:
All
Ages:
Between 60 years and 85 years
Trial Updated:
05/24/2024
Locations: CenExel iResearch, LLC, Savannah, Georgia
Conditions: Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
Register for Updates
Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)
NCT06285240
Recruiting
The main purpose of this study is to assess the safety and efficacy of MK-1167 administered to participants with Alzheimer's Disease (AD) receiving stable Donepezil treatment.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
05/13/2024
Locations: CenExel iResearch, LLC ( Site 0004), Savannah, Georgia
Conditions: Alzheimer's Disease
Register for Updates
Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry
NCT05999084
Recruiting
The purpose of this registry is to compile information on patients who are receiving FDA-approved anti-amyloid mAbs in the course of their clinic visits in the Emory Cognitive Neurology Clinic and in Georgia Memory Net Memory Assessment Clinics.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
03/27/2024
Locations: Georgia Memory Net Memory Assessment Clinic - Savannah, Savannah, Georgia
Conditions: Alzheimer Disease
Register for Updates